Scholarlink

<p>This consensus on advanced epithelial ovarian cancer was focused on issues not covered by existing international guidelines, some country-specific issues, and general and technical aspects of cytoreductive surgery (CRS). The modified Delphi technique was employed with two rounds of voting. There were 47 close-ended questions on 7 key topics that were disseminated through the SurveyMonkey (<a href="http://www.surveymonkey.com">www.surveymonkey.com</a>) platform. Out of 54 invited surgical and gynecologic oncologists, 48 agreed to vote. A consensus was reached if any one option received &gt; 70% votes (strong consensus—&gt; 90%votes). The response rate was 100% in round 1 and 95.8% in round 2. A consensus was reached on 32/47(68.0%) questions, with strong consensus on 10/47 (21.2%). The panel recommended neoadjuvant chemotherapy (NACT) for patients with positive pleural cytology, and resection of regions involved prior to NACT for stage III-C and only resection of sites of residual disease for stage IV patients. For both primary and secondary CRS, using a combination of clinical and radiological features and validated predictive scores was recommended for patient selection. There was a strong consensus that hyperthermic intraperitoneal chemotherapy (HIPEC) should be added to interval CRS for high-grade serous and mucinous carcinomas, but no consensus on its use in stage IV-A disease. Visceral resections and lymphadenectomy were not recommended in absence of overt disease or suspicion of disease. The panel reached a consensus on many technical aspects of CRS and issues related to HIPEC. These recommendations should be a useful clinical guide for surgeons treating ovarian cancer. Some recommendations could change as new evidence comes in.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The INDEPSO-ISPSM Consensus on Peritoneal Malignancies—Management of Advanced Epithelial Ovarian Cancer

  • 期刊论文

  • 发表日期：

    2025年4月29日

查看全文
  • Neha Kumar,
  • Aditi Bhatt,
  • Snita Sinukumar,
  • Ajinkya Pawar,
  • Geetu Bhandoria,
  • Niharika Garach,
  • Anik Ghosh,
  • Rohit Kumar,
  • Deepti Mishra,
  • Swapnil Patel,
  • Vivek Sukumar,
  • Mukurdipi Ray,
  • Somashekhar SP

摘要

This consensus on advanced epithelial ovarian cancer was focused on issues not covered by existing international guidelines, some country-specific issues, and general and technical aspects of cytoreductive surgery (CRS). The modified Delphi technique was employed with two rounds of voting. There were 47 close-ended questions on 7 key topics that were disseminated through the SurveyMonkey (www.surveymonkey.com) platform. Out of 54 invited surgical and gynecologic oncologists, 48 agreed to vote. A consensus was reached if any one option received > 70% votes (strong consensus—> 90%votes). The response rate was 100% in round 1 and 95.8% in round 2. A consensus was reached on 32/47(68.0%) questions, with strong consensus on 10/47 (21.2%). The panel recommended neoadjuvant chemotherapy (NACT) for patients with positive pleural cytology, and resection of regions involved prior to NACT for stage III-C and only resection of sites of residual disease for stage IV patients. For both primary and secondary CRS, using a combination of clinical and radiological features and validated predictive scores was recommended for patient selection. There was a strong consensus that hyperthermic intraperitoneal chemotherapy (HIPEC) should be added to interval CRS for high-grade serous and mucinous carcinomas, but no consensus on its use in stage IV-A disease. Visceral resections and lymphadenectomy were not recommended in absence of overt disease or suspicion of disease. The panel reached a consensus on many technical aspects of CRS and issues related to HIPEC. These recommendations should be a useful clinical guide for surgeons treating ovarian cancer. Some recommendations could change as new evidence comes in.